Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelics as a novel approach to treating autoimmune conditions
Caitlin Thompson, Attila Szabó
Immunology Letters (2020) Vol. 228, pp. 45-54
Open Access | Times Cited: 63

Showing 1-25 of 63 citing articles:

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Antonio Inserra, Danilo De Gregorio, Gabriella Gobbi
Pharmacological Reviews (2020) Vol. 73, Iss. 1, pp. 202-277
Open Access | Times Cited: 163
The clinical pharmacology and potential therapeutic applications of 5‐methoxy‐N,N‐dimethyltryptamine (5‐MeO‐DMT)
Johannes T. Reckweg, Malin V. Uthaug, Attila Szabó, et al.
Journal of Neurochemistry (2022) Vol. 162, Iss. 1, pp. 128-146
Open Access | Times Cited: 61
Associations between lifetime classic psychedelic use and markers of physical health
Otto Simonsson, James Sexton, Peter S. Hendricks
Journal of Psychopharmacology (2021) Vol. 35, Iss. 4, pp. 447-452
Open Access | Times Cited: 56
Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: An experimental, placebo-controlled study
Natasha L. Mason, Attila Szabó, Kim P. C. Kuypers, et al.
Brain Behavior and Immunity (2023) Vol. 114, pp. 299-310
Open Access | Times Cited: 39
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Josh Allen, Shannon Dames, Claire J. Foldi, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 3, pp. 671-685
Closed Access | Times Cited: 13
Psychedelics, Sociality, and Human Evolution
José Manuel Rodríguez Arce, Michael Winkelman
Frontiers in Psychology (2021) Vol. 12
Open Access | Times Cited: 51
Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective
John R. Kelly, Claire M. Gillan, Jack Prenderville, et al.
Frontiers in Psychiatry (2021) Vol. 12
Open Access | Times Cited: 51
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Salma Laabi, Claire LeMmon, Callie Vogel, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111753-111753
Closed Access | Times Cited: 6
Associations between lifetime classic psychedelic use and cardiometabolic diseases
Otto Simonsson, Walter Osika, Robin Carhart‐Harris, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 38
New Paradigms of Old Psychedelics in Schizophrenia
Danish Mahmood, Sattam Khulaif Alenezi, Md Jamir Anwar, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 640-640
Open Access | Times Cited: 25
The potential of psychedelics for the treatment of Alzheimer's disease and related dementias
Michael Winkelman, Attila Szabó, Ede Frecska
European Neuropsychopharmacology (2023) Vol. 76, pp. 3-16
Open Access | Times Cited: 14
Use of Psychedelics for Pain: A Scoping Review
Akash Goel, Yeshith Rai, Shayan Sivadas, et al.
Anesthesiology (2023) Vol. 139, Iss. 4, pp. 523-536
Closed Access | Times Cited: 14
Psychedelics and Anti-inflammatory Activity in Animal Models
Thomas W. Flanagan, Charles D. Nichols
Current topics in behavioral neurosciences (2022), pp. 229-245
Closed Access | Times Cited: 20
Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain
Elaine Meade, Sarah Hehir, Neil J. Rowan, et al.
Journal of Fungi (2022) Vol. 8, Iss. 3, pp. 290-290
Open Access | Times Cited: 19
Psychedelic Experience
Aidan Lyon
Oxford University Press eBooks (2023)
Closed Access | Times Cited: 12
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Blerida Banushi, Vince Polito
Biology (2023) Vol. 12, Iss. 11, pp. 1380-1380
Open Access | Times Cited: 12
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh, et al.
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108641-108641
Open Access | Times Cited: 4
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity
Daniel A Kinderlehrer
Neuropsychiatric Disease and Treatment (2025) Vol. Volume 21, pp. 141-155
Open Access
Cardiovascular effects and safety of classic psychedelics
Acile Nahlawi, Leon M. Ptaszek, Jeremy N. Ruskin
Nature Cardiovascular Research (2025)
Closed Access
Lifetime classic psychedelic use and headaches: A cross-sectional study
Zusanna Bjurenfalk, Alva Cosmo, Otto Simonsson, et al.
Journal of Psychopharmacology (2025)
Closed Access
Association Between Lifetime Classic Psychedelic Use and Hypertension in the Past Year
Otto Simonsson, Peter S. Hendricks, Robin Carhart‐Harris, et al.
Hypertension (2021) Vol. 77, Iss. 5, pp. 1510-1516
Open Access | Times Cited: 27
Catalysts for change: the cellular neurobiology of psychedelics
Matthew I. Banks, Zarmeen Zahid, N. Jones, et al.
Molecular Biology of the Cell (2021) Vol. 32, Iss. 12, pp. 1135-1144
Open Access | Times Cited: 26
Effects of repeated lysergic acid diethylamide (LSD) on the mouse brain endocannabinoidome and gut microbiome
Antonio Inserra, Giada Giorgini, Sébastien Lacroix, et al.
British Journal of Pharmacology (2022) Vol. 180, Iss. 6, pp. 721-739
Closed Access | Times Cited: 18
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis
John R. Kelly, Gerard Clarke, Andrew Harkin, et al.
International Journal of Clinical and Health Psychology (2022) Vol. 23, Iss. 2, pp. 100349-100349
Open Access | Times Cited: 16
Psychedelics for Brain Injury: A Mini-Review
M. Ijaz Khan, Gregory T. Carter, Sunil Aggarwal, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 22
Page 1 - Next Page

Scroll to top